Dual Anti-Mesothelin/Anti-B7-H3 CAR T-Cell Therapy (Nanjing CART Medical Technologies)

N/A

Report date: 2025/01/26 18:09:21

Base Information

Drug NameDual Anti-Mesothelin/Anti-B7-H3 CAR T-Cell Therapy (Nanjing CART Medical Technologies)
Drug Alias NameDual Anti-CD276/Anti-B7-H3 CAR T-Cell Therapy (Nanjing CART Medical Technologies)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionMesothelin modulatorsCD276 antigen modulators
TargetsMesothelinCD276 antigen
Therapy Area/IndicationsSolid tumoursPancreatic NeoplasmsTriple Negative Breast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesNanjing Kati Medical Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Kati Medical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursPancreatic NeoplasmsTriple Negative Breast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A